Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89,414,894
-
Number of holders
-
153
-
Total 13F shares, excl. options
-
72,978,794
-
Shares change
-
+1,941,256
-
Total reported value, excl. options
-
$1,535,405,782
-
Value change
-
+$36,464,951
-
Put/Call ratio
-
115%
-
Number of buys
-
83
-
Number of sells
-
-80
-
Price
-
$21.03
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q4 2022
186 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2022.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 153 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 72,978,794 shares
of 89,414,894 outstanding shares and own 82% of the company stock.
Largest 10 shareholders include ARMISTICE CAPITAL, LLC (6,412,000 shares), BlackRock Inc. (5,094,388 shares), JANUS HENDERSON GROUP PLC (5,091,285 shares), Deep Track Capital, LP (4,582,000 shares), STATE STREET CORP (4,224,024 shares), RA CAPITAL MANAGEMENT, L.P. (3,984,681 shares), MACQUARIE GROUP LTD (3,556,112 shares), VANGUARD GROUP INC (3,515,446 shares), GOLDMAN SACHS GROUP INC (2,640,146 shares), and ADAGE CAPITAL PARTNERS GP, L.L.C. (2,600,000 shares).
This table shows the top 153 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.